Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study.

Front Oncol · 2021 · PMC8763847 · PMID 35059312

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

borderline significancep = 0.076so close (0.05 < p ≤ 0.1)

The inclusion of rituximab improved the 5-year OS, with borderline significance (62.5% vs . 55.2%, p = 0.076).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.